Sugi Predict

Sugi Predict / Compounds / SCHEMBL4479900

SCHEMBL4479900

SCHEMBL4479900

Cc1ccc(S(=O)(=O)Oc2cccc3c(S(=O)(=O)NCc4ccc(C)o4)cccc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ ESR1 P03372 2/20 0.50
▸ ESR2 Q92731 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HPGD P15428 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ CYP19A1 P11511 1/20 0.38
▸ HTR6 P50406 1/20 0.37
▸ RXFP1 Q9HBX9 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ NSD2 O96028 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482026 0.83 CA12 (0.56) KMT2AMEN1GAAESR1ESR2
SCHEMBL4483773 0.82 MEN1 (0.60) KMT2AMEN1GAAESR1ESR2
SCHEMBL4483934 0.81 MEN1 (0.52) KMT2AMEN1GAAESR1ESR2
SCHEMBL4470893 0.81 MEN1 (0.52) KMT2AMEN1GAAESR1ESR2
SCHEMBL4492832 0.80 MEN1 (0.51) KMT2AMEN1GAAESR1ESR2
SCHEMBL4492967 0.80 KMT2A (0.51) KMT2AMEN1GAAESR1ESR2
SCHEMBL4473385 0.79 MEN1 (0.50) KMT2AMEN1GAAESR1ESR2
SCHEMBL4483280 0.78 CYP19A1 (0.50) KMT2AMEN1GAAESR1ESR2
SCHEMBL4475681 0.78 MEN1 (0.50) KMT2AMEN1GAAESR1ESR2
SCHEMBL4489698 0.78 NSD2 (0.49) KMT2AMEN1GAAESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 — — US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 — — US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 — — US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 KMT2A 1012/4885MEN1 4507/4885GAA 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.